RABV antigenic peptide loaded polymeric nanoparticle production, characterization, and preliminary investigation of its biological activity.

Autor:	Bezir K; Faculty of Engineering and Natural Sciences, Bioengineering Department, Bursa Technical University, Bursa, Turkey., Pelit Arayici P; Faculty of Chemical and Metallurgical Engineering, Bioengineering Department, Yildiz Technical University, Istanbul, Turkey.; Health Biotechnology Joint Research and Application Center of Excellence, 34220 Esenler, Istanbul, Turkey., Akgül B; Faculty of Chemical and Metallurgical Engineering, Bioengineering Department, Yildiz Technical University, Istanbul, Turkey., Abamor EŞ; Faculty of Chemical and Metallurgical Engineering, Bioengineering Department, Yildiz Technical University, Istanbul, Turkey., Acar S; Faculty of Chemical and Metallurgical Engineering, Bioengineering Department, Yildiz Technical University, Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	Nanotechnology [Nanotechnology] 2024 Oct 18; Vol. 36 (2). Date of Electronic Publication: 2024 Oct 18.
DOI:	10.1088/1361-6528/ad84fe
Abstrakt:	Nanoparticle-based antigen carrier systems have become a significant area of research with the advancement of nanotechnology. Biodegradable polymers have emerged as particularly promising carrier vehicles due to their ability to address the limitations of existing vaccine systems. In this study, we successfully encapsulated the G5-24 linear peptide, located between amino acids 253 and 275 in the primary sequence of the rabies virus G protein, into biodegradable and biocompatible PLGA copolymer using the double emulsion solvent evaporation method. The resulting nanoparticles had a size of approximately 230.9 ± 0.9074 nm, with a PDI value of 0.168 ± 0.017 and a zeta potential value of -9.86 ± 0.132 mV. SEM images confirmed that the synthesized nanoparticles were uniform in size and distribution. Additionally, FTIR spectra indicated successful peptide loading into the nanoparticles. The encapsulation efficiency of the peptide-loaded nanoparticles was 73.3%, with a peptide loading capacity of 48.2% and a reaction yield of 30.4%. Peptide release studies demonstrated that 65.55% of the peptide was released in a controlled manner over 28 d, following a 'biphasic burst release' profile consistent with the degradation profile of PLGA. This controlled release is particularly beneficial for vaccine studies. Cytotoxicity tests revealed that the R-NP formulation did not induce cytotoxicity in fibroblast cells and enhanced NO production in macrophages, indicating its potential for vaccine development. (Creative Commons Attribution license.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu